Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials

[cafead]

via Gilead Sciences (GILD.O) said on Thursday enrollments to test its cancer drug, magrolimab, on solid tumors had been paused globally, a week after the U.S. regulator put some studies on hold following increased risk of patient deaths.

article source